Wegovy HD vs Zepbound: The 2026 Injectable GLP-1 Showdown
As of 2026, two of the most powerful weight-loss injectables — Wegovy HD (7.2 mg semaglutide) and Zepbound (15 mg tirzepatide) — are in direct competition. Both have demonstrated remarkable efficacy in pivotal clinical trials, but their differences in mechanism, side effect profiles, and patient access pathways make the choice highly individualized. This guide breaks down the key factors to help you and your provider decide which may be the better fit.
Weight Loss Results: How Do They Compare?
Both drugs deliver significant, clinically meaningful weight loss — and the numbers are strikingly close:
- Wegovy HD 7.2 mg: ~20.7% average body weight loss at 72 weeks (STEP UP trial)
- Zepbound 15 mg: ~20.9% average body weight loss at 72 weeks (SURMOUNT-1 trial)
While Zepbound edges out by a fraction in the headline data, the difference is not clinically significant. Both are considered among the most effective pharmaceutical weight-loss treatments ever approved. It's important to note these were separate trials with different patient populations, so a direct head-to-head comparison is not available.
Mechanism of Action: GLP-1 vs Dual GIP/GLP-1
The core pharmacological difference between these drugs is fundamental:
- Wegovy HD (semaglutide): A pure GLP-1 receptor agonist. It mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
- Zepbound (tirzepatide): A dual GIP and GLP-1 receptor agonist. It targets both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways simultaneously, potentially enhancing satiety signals and metabolic benefits through complementary mechanisms.
Some researchers believe tirzepatide's dual-agonist approach may offer advantages for patients with type 2 diabetes specifically, since GIP plays a role in insulin secretion. However, for pure weight loss, both drugs have delivered nearly identical outcomes in their respective trials.
Feature Comparison: Wegovy HD 7.2 mg vs Zepbound 15 mg
| Feature | Wegovy HD 7.2 mg | Zepbound 15 mg |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Weight Loss (72 weeks) | ~20.7% | ~20.9% |
| Dosing Frequency | Weekly injection | Weekly injection |
| Dose Escalation | 0.25 → 0.5 → 1 → 1.7 → 2.4 → 7.2 mg | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg |
| FDA Approval Date | March 19, 2026 | November 2023 |
| Manufacturer | Novo Nordisk | Eli Lilly |
| List Price (per month) | ~$1,349 | ~$1,060 |
| Dysesthesia Risk | ~4% | Not reported |
Insurance Coverage and Access
Both drugs typically require prior authorization from insurance. Key differences in the access pathway:
- Wegovy HD: If you're already on Wegovy 2.4 mg and your provider documents a plateau, upgrading to HD is a dose escalation within the same medication. This is usually simpler to approve than switching drug classes entirely. Novo Nordisk's savings card applies to HD as well — most commercial patients pay $0–$25/month.
- Zepbound: Switching from semaglutide to tirzepatide requires a new prior authorization, which may involve step therapy requirements or a documented failure on the current therapy. Eli Lilly offers its own savings program with similar copay assistance for eligible patients.
For patients already established on Wegovy, the administrative path to HD is significantly easier than switching to Zepbound.
Side Effect Comparison
Both drugs share common GLP-1-class gastrointestinal side effects:
- Nausea: ~30% (Wegovy HD) vs ~28% (Zepbound)
- Diarrhea: ~20% vs ~18%
- Vomiting: ~15% vs ~14%
However, Wegovy HD has a unique safety signal: dysesthesia (altered skin sensation including burning and tingling) was reported in ~4% of patients in the STEP UP trial — a finding not observed in Zepbound's clinical program. Zepbound, on the other hand, has a slightly higher rate of injection-site reactions.
Upgrade vs Switch: The Practical Decision
For patients currently on Wegovy 2.4 mg who have hit a weight loss plateau, the decision framework is straightforward:
- Upgrade to Wegovy HD 7.2 mg: Simplest path — same drug, same brand, same pharmacy, same dosing schedule. Lower administrative burden, no new prior auth in most cases. Ideal if you've tolerated 2.4 mg well and simply need a higher dose.
- Switch to Zepbound 15 mg: May be worth considering if you've had incomplete response to semaglutide specifically, or if your provider believes the dual GIP/GLP-1 mechanism might offer additional metabolic benefits. Requires new prior authorization and a potentially different titration schedule.
For many patients, upgrading within the same drug is the most practical first step. If Wegovy HD doesn't deliver sufficient additional weight loss after 3–6 months, switching to Zepbound remains an option.
Prefer a daily pill? Oral GLP-1 options from $99/mo
Not ready for the higher dose injection? MEDVi offers oral GLP-1 tablets and pills alongside injectables — a provider helps you choose.
See Oral GLP-1 Options →Medical Disclaimer
Wegovy HD and Zepbound are prescription medications for chronic weight management. This comparison is for informational purposes only and does not constitute medical advice. Individual results vary based on health status, genetics, lifestyle factors, and adherence. Always consult your healthcare provider to determine the best treatment path for your specific health goals and conditions.